Core Insights - The discussion focuses on the potential of cell therapy, particularly in the hematology space, highlighting current advancements and future innovations [1][2] Company Insights - Bristol's Head of the cell therapy business, Lynelle, is involved in the conversation, indicating the company's commitment to this area of research and development [1] - The company is positioned to leverage proof points from existing therapies while exploring innovative solutions in the cell therapy sector [2] Industry Insights - The cell therapy market is experiencing significant innovation, with expectations for growth and new applications in hematology [2] - The conversation aims to provide insights into the current landscape of cell therapy and its future trajectory within the industry [1][2]